Patents by Inventor Steven C. Quay

Steven C. Quay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE
    Publication number: 20100184688
    Abstract: Pharmaceutical compositions and methods are described comprising at least a parathyroid hormone peptide (PTH) preferably PTH1-34 and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of PTH, for treating or preventing osteoporosis or osteopenia in a mammalian subject, preferably a human.
    Type: Application
    Filed: March 17, 2010
    Publication date: July 22, 2010
    Applicant: MDRNA, INC.
    Inventors: Steven C. Quay, Henry R. Costantino, Mary S. Kleppe, Ching-Yuan Li
  • NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB FAMILY GENE EXPRESSION AND USES THEREOF
    Publication number: 20100112687
    Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing one or more ERBB family gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to one or more ERBB family mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine and optionally other modifications or combinations thereof. Also provided are methods of decreasing expression of one or more ERBB family gene in a cell or in a subject to treat one or more ERBB family-related disease.
    Type: Application
    Filed: February 28, 2008
    Publication date: May 6, 2010
    Applicant: MDRNA, INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • NUCLEIC ACID COMPOUNDS FOR INHIBITING GENE EXPRESSION AND USES THEREOF
    Publication number: 20100105134
    Abstract: The present disclosure provides RNA molecules, for example, meroduplex ribonucleic acid molecules (mdRNA), and blunt ended double-stranded ribonucleic acid molecules capable of decreasing or silencing expression of a target gene. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target mRNA. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease or condition associated with the target gene.
    Type: Application
    Filed: September 1, 2009
    Publication date: April 29, 2010
    Applicant: MDRNA, Inc.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • NUCLEIC ACID COMPOUNDS FOR INHIBITING MYC GENE EXPRESSION AND USES THEREOF
    Publication number: 20100055782
    Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing MYC gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-over-lapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a MYC mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a MYC gene in a cell or in a subject to treat a MYC-related disease.
    Type: Application
    Filed: March 3, 2008
    Publication date: March 4, 2010
    Applicant: MDRNA, INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • NUCLEIC ACID COMPOUNDS FOR INHIBITING RAS GENE EXPRESSION AND USES THEREOF
    Publication number: 20100055783
    Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing RAS (e.g., HRAS, KRAS, NRAS) gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an HRAS, KRAS, or NRAS mRNA. In addition, the meroduplex may have at least one uridine is a 5-methyluridine, a nucleoside is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a RAS gene in a cell or in a subject to treat a RAS-related disease.
    Type: Application
    Filed: March 3, 2008
    Publication date: March 4, 2010
    Applicant: MDRNA, INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • NUCLEIC ACID COMPOUNDS FOR INHIBITING WNT GENE EXPRESSION AND USES THEREOF
    Publication number: 20100055784
    Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing WNT1, WNT2, or WNT3A gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a WNT1, WNT2, or WNT3A mRNA. In addition, the meroduplex may have at least one uridine is a 5-methyluridine, a nucleoside is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a WNT1, WNT2, or WNT3A gene in a cell or in a subject to treat a WNT1, WNT2, or WNT3A-related disease.
    Type: Application
    Filed: March 3, 2008
    Publication date: March 4, 2010
    Applicant: MDRNA, INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • NUCLEIC ACID COMPOUNDS FOR INHIBITING VEGF FAMILY GENE EXPRESSION AND USES THEREOF
    Publication number: 20100047909
    Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing one or more VEGF family gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to one or more VEGF family mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine and optionally other modifications or combinations thereof. Also provided are methods of decreasing expression of one or more VEGF family gene in a cell or in a subject to treat one or more VEGF family-related disease.
    Type: Application
    Filed: February 28, 2008
    Publication date: February 25, 2010
    Applicant: MDRNA, INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • NUCLEIC ACID COMPOUNDS FOR INHIBITING BCL2 GENE EXPRESSION AND USES THEREOF
    Publication number: 20100041140
    Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing BCL2 gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-over-lapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a BCL2 mRNA. In addition, the meroduplex may have at least one uridine is a 5-methyluridine, a nucleoside is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a BCL2 gene in a cell or in a subject to treat a BCL2-related disease.
    Type: Application
    Filed: February 29, 2008
    Publication date: February 18, 2010
    Applicant: MDRNA, INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • PRODUCTION AND USE OF DERIVATIZED HOMOSERINE LACTONES
    Publication number: 20100016424
    Abstract: The present invention provides analogues of autoinducer molecules that are derivatized to allow their attachment to other molecules and surfaces. Libraries of the autoinducer analogues are also contemplated. Also provided are methods for using the compounds of the invention to produce compositions, such as immunoconjugates, antibodies and vaccines, which are useful for treating and preventing disease states in a subject. The compositions of the invention are also useful in various assays, including assessing the autoinducer load in a subject.
    Type: Application
    Filed: July 13, 2009
    Publication date: January 21, 2010
    Applicant: Ensisheim Partners LLC
    Inventor: Steven C. Quay
  • RIBONUCLEIC ACIDS WITH NON-STANDARD BASES AND USES THEREOF
    Publication number: 20100015708
    Abstract: The present disclosure provides a ribonucleic acid comprising a double-stranded region having at least one base pair comprising a 5-methyluridine base paired with a 2,6-diaminopurine and methods for preparing the same. Also provided are methods for treating or preventing a disease or disorder by inducing RNAi.
    Type: Application
    Filed: June 18, 2009
    Publication date: January 21, 2010
    Applicant: MDRNA, INC.
    Inventors: Steven C. Quay, Narendra K. Vaish
  • NUCLEIC ACID COMPOUNDS FOR INHIBITING HIF1A GENE EXPRESSION AND USES THEREOF
    Publication number: 20100015706
    Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing HIF1A gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a HIF1A mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a HIF1A gene in a cell or in a subject to treat a HIF1A-related disease.
    Type: Application
    Filed: February 28, 2008
    Publication date: January 21, 2010
    Applicant: MDRNA, INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS
    Publication number: 20090220435
    Abstract: Compounds and components including sequences for mucosal epithelial transport of an active agent are given. Tight junction modulating peptide components are described for use in transport and delivery. Permeability can be enhanced with reversibility. Compounds and components for enhanced delivery may be peptide or protein variants, conjugates, or other analog types and structures.
    Type: Application
    Filed: July 27, 2006
    Publication date: September 3, 2009
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Steven C. Quay, Shu-Chih Chen Quay, Kunyuan Cui, Anthony P. Sileno, Paul Hickok Johnson, Michael E. Houston, Henry R. Costantino, Michael V. Templin
  • Production and use of derivatized homoserine lactones
    Patent number: 7560572
    Abstract: The present invention provides analogues of autoinducer molecules that are derivatized to allow their attachment to other molecules and surfaces. Libraries of the autoinducer analogues are also contemplated. Also provided are methods for using the compounds of the invention to produce compositions, such as immunoconjugates, antibodies and vaccines, which are useful for treating and preventing disease states in a subject. The compositions of the invention are also useful in various assays, including assessing the autoinducer load in a subject.
    Type: Grant
    Filed: January 13, 2004
    Date of Patent: July 14, 2009
    Assignee: K-Quay Enterprises, LLC
    Inventor: Steven C. Quay
  • COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF PEPTIDE YY FOR TREATING OBESITY
    Publication number: 20090118158
    Abstract: Pharmaceutical compositions comprising PYY(3-36), a cyclodextrin, and a compound selected from phosphatidylcholine or diglyceride, wherein the PYY(3-36) is present in an amount effective to alleviate one or more symptom(s) of obesity in a subject, and the cyclodextrin and the compound selected from phosphatidylcholine or diglyceride are present in an amount sufficient to enhance epithelial permeation.
    Type: Application
    Filed: September 19, 2008
    Publication date: May 7, 2009
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventor: Steven C. Quay
  • MODIFICATION OF DOUBLE-STRANDED RIBONUCLEIC ACID MOLECULES
    Publication number: 20090018097
    Abstract: A double-stranded RNA (dsRNA) molecule comprising between about 15 base pairs and about 40 base pairs, wherein at least one ribonucleotide of the dsRNA is a 5?-methyl-pyrimidine and/or at least one 2?-O-methyl ribonucleotide, and a method of improving ribonuclease stability, reducing off-target effects of a double stranded siRNA molecule, or of reducing interferon responsiveness of a double stranded siRNA molecule using such dsRNA.
    Type: Application
    Filed: May 25, 2006
    Publication date: January 15, 2009
    Applicant: MDRNA, INC
    Inventors: Steven C. Quay, Kunyuan Cui, Paul H. Johnson, Lishan Chen, Mohammad Ahmadian
  • AMINO ACID LIPIDS AND USES THEREOF
    Publication number: 20080317839
    Abstract: This disclosure provides a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.
    Type: Application
    Filed: May 2, 2008
    Publication date: December 25, 2008
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Steven C. Quay, Michael Houston, JR., Pierrot Harvie, Roger C. Adami, Renata Fam, Mary Gallagher Prieve, Kathy Lynn Fosnaugh, Shaguna Seth
  • Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
    Publication number: 20080318837
    Abstract: What is described is a pharmaceutical formulation comprising a mixture of a pharmaceutically effective amount of glucose-regulating peptide (GRP) and enhancers, wherein the pharmaceutical formulation is used in the treatment of a metabolic syndrome.
    Type: Application
    Filed: December 1, 2006
    Publication date: December 25, 2008
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Steven C. Quay, Henry R. Costantino, Michael V. Templin, Alexis Kays Leonard, Mary S. Kleppe, Joshua O. Sestak
  • Mucosal Delivery of Stabilized Formulations of Exendin
    Publication number: 20080318861
    Abstract: What is described is a pharmaceutical formulation for intranasal administration of exendin to a mammal, wherein the formulation comprises a therapeutically effective amount of an exendin, a viscosity enhancer, methyl-?-cyclodextrin, a surfactant, tartrate buffer to control pH and a chelating agent for cations, and wherein such exendin dosage form exhibits at least 95% exenatide recovery after storage for at least 365 days at 5° C.
    Type: Application
    Filed: December 7, 2006
    Publication date: December 25, 2008
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Steven C. Quay, Henry R. Costantino, Alexis Kays Leonard
  • NUCLEIC ACID COMPOUNDS FOR INHIBITING APOB GENE EXPRESSION AND USES THEREOF
    Publication number: 20080299659
    Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing ApoB gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an ApoB mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of an ApoB gene in a cell or in a subject to treat an ApoB-related disease.
    Type: Application
    Filed: February 28, 2008
    Publication date: December 4, 2008
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • NUCLEIC ACID COMPOUNDS FOR INHIBITING AKT GENE EXPRESSION AND USES THEREOF
    Publication number: 20080293136
    Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing AKT gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an AKT mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of an AKT gene in a cell or in a subject to treat an AKT-related disease.
    Type: Application
    Filed: February 28, 2008
    Publication date: November 27, 2008
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian